CompletedNCT00140426
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Eating disorders
Medication studyAges 12–21United States
Understand this study
Who was this study for?
Listed age limits: 12 years to 21 years.
- Listed locations
- DenverSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 12 Years to 21 Years
- Official registry ID
- NCT00140426
- Official title
Show the full official title
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Recruitment & locations
CompletedDenver
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Did this study involve medication?
Yes. The study involved medication, including Risperidone and Placebo.
Who was this study for?
Listed age limits: 12 years to 21 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me